NRC Health (National Research Corporation) — 2023 Form 10-K
Business context and reporting period. NRC Health provides subscription-based analytics, research, and technology focused on patient and employee experience, reputation, engagement, and healthcare governance. This annual report covers the fiscal year ended December 31, 2023; it does not provide a clear standalone fourth-quarter financial summary.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $148.6 million | $151.6 million | Down 2% |
| Operating income / margin | $40.0 million / 27% | $46.5 million / 31% | Income down 14%; margin down 4 percentage points |
| Net income | $31.0 million | $31.8 million | Down 3% |
| Diluted EPS | $1.25 | $1.27 | Down 2% |
| Cash from operating activities | $38.1 million | $36.3 million | Up 5% |
| Capital expenditures | $15.8 million | $9.8 million | Up $5.9 million |
| Recurring contract value | $141.9 million | $146.8 million | Down 3% |
Cash from operations less capital expenditures was approximately $22.3 million in 2023, a simple derived measure rather than a company-reported free-cash-flow metric. Cash and cash equivalents fell to $6.7 million from $25.0 million. The working-capital position shifted from a $10.3 million surplus to an $11.8 million deficit.
At year-end, debt included a $17.8 million fixed-rate term loan and $19.0 million delayed-draw term loan; the $30 million revolving facility had no outstanding balance. The delayed-draw facility had $56 million available, but is restricted to permitted acquisitions or share repurchases. The company reported covenant compliance and stated liquidity sources should meet foreseeable capital and debt needs. Debt is secured by substantially all company assets.
Material changes versus 2022
- Revenue fell by approximately $3.0 million. The Canadian office closure eliminated $793,000 of 2022 revenue; U.S. revenue also declined, including lower recurring revenue from existing clients and new-customer sales.
- Recurring contract value declined as the company focused on core digital solutions and recorded lower net sales, though management said the trend improved later in 2023.
- Operating income and margin decreased amid lower revenue, higher marketing and technology investment, and increased data-collection costs. SG&A rose 9% to $46.6 million.
- Operating cash flow increased, but cash balances declined largely due to dividends and share repurchases. The company repurchased $19.1 million of shares in 2023 and paid $36.4 million in dividends.
- Other expense was substantially lower than in 2022, when the company recorded a $2.6 million foreign-currency translation loss following the liquidation of its Canadian subsidiary.
Outlook, risks, and notable items
- No quantified revenue, earnings, or margin guidance is provided. Management expects inflationary pressures to continue in 2024 and salary and benefit costs to rise due to new executive roles and commission changes; it expects efficiency and cost controls to provide offsets.
- Headquarters renovations are expected to be completed in 2025. Estimated remaining costs are $11.6 million in 2024 and $1.4 million in 2025, expected to be funded through operating cash flow and revolving borrowings.
- Management expects interest expense to increase and interest income to decrease in future periods, reflecting expected borrowing and lower money-market investments.
- Key risks include annual contract renewal and client retention, healthcare-sector budget pressure and consolidation, competition and pricing, data collection and third-party vendor reliance, cybersecurity and privacy incidents, technology execution, and inflation. The company disclosed prior cyber incidents in 2020 and 2022 that temporarily disrupted services; it reported no protected data was compromised or exfiltrated in those incidents.
- Management said ordinary-course litigation is not expected to materially affect financial position, results, or liquidity. The auditor issued unqualified opinions on the financial statements and internal controls; a critical audit matter concerned audit evidence for key terms in new and modified subscription agreements.
Important facts for investors to verify
- Whether renewals, new-client sales, and recurring contract value stabilize after the 2023 decline.
- Whether the operating-margin decline reverses as marketing, technology, and data-collection spending develop into revenue and productivity gains.
- Cash needs and covenant headroom after dividends, buybacks, renovation spending, and any additional delayed-draw borrowing.
- Actual renovation costs and schedule, and the effect of variable-rate debt on interest expense.
- Progress in executive and CFO transitions, including the announced CFO retirement effective March 31, 2024.
- Whether cybersecurity controls and third-party safeguards remain effective, and whether any new incident leads to service interruption, costs, or client losses.